Strides Pharma US Facility Receives Four FDA Observations Following Routine Inspection
Key Insights
Strides Pharma Inc (search)'s Chestnut Ridge facility in New York underwent a routine FDA cGMP inspection from December 17-23, 2025, resulting in four procedural observations.
The company stated that the observations are procedural in nature and will not impact the supply of commercial products from the facility.
Strides Pharma reported strong Q2 financial performance with net profit rising 82% year-on-year to ₹131.5 crore and revenue increasing 4.6% to ₹1,221 crore.
Strides Pharma Science Ltd (search) announced that its US subsidiary received four observations from the Food and Drug Administration following a routine inspection at its New York manufacturing facility. The inspection, conducted between December 17-23, 2025, at the Chestnut Ridge formulations facility of Strides Pharma Inc (search) (SPI), concluded with the FDA issuing a Form 483 containing four observations.
Inspection Details and Company Response
The FDA conducted a routine current Good Manufacturing Practices (cGMP) inspection at the formulations facility of SPI, a step-down wholly-owned subsidiary of Strides Pharma Science Limited. According to the company, the observations are procedural in nature and are not expected to impact the supply of commercial products from the facility.
Strides Pharma stated it will submit a comprehensive response to the regulator within the stipulated timeline and expressed confidence in addressing all observations to the FDA's satisfaction.
Strong Financial Performance Amid Regulatory Activity
Despite the regulatory inspection, Strides Pharma reported robust financial results for the second quarter. The company's net profit surged 82% year-on-year to ₹131.5 crore, compared with ₹72.2 crore in the corresponding period last year.
Revenue for the quarter increased 4.6% year-on-year to ₹1,221 crore. Earnings before interest, tax, depreciation and amortisation (EBITDA) grew 25.4% to ₹232 crore, while the EBITDA margin expanded by over 300 basis points to 19% from 15.8% a year ago.
The company's operational efficiency showed marked improvement, with gross margin expanding by 500 basis points to 57.8% in the quarter, compared with 52.8% in the year-ago period.
Market Impact
Following the announcement, shares of Strides Pharma Science Ltd (search) ended lower on Wednesday, December 24, declining 3.59% to ₹936 on the NSE, reflecting investor caution regarding the FDA observations despite the company's assurance of minimal operational impact.